Finally, in this study, we found that the low-risk AML patients may benefit more from traditional chemotherapeutic drugs (cytarabine, doxorubicin, docetaxel, and etoposide); low-risk patients may also perform better to both sorafenib and midostaurin that are used for AML patients with FLT3 mutations and to the hedgehog inhibitor GDC-0449 (Vismodegib), while high-risk patients will have better responses to the BCL-2 inhibitor ABT-263. The gene discussed is BCL2; the disease is acute myeloid leukemia.